Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564562 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02564562 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 6 participants.
The verdict
NCT02564562, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The study aims to understand, using radiolabelled PF-06463922, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.
Interventions
- DRUG [14C] PF-06463922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564562
The ClinicalTrials.gov registry entry for NCT02564562 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C] PF-06463922 is the first listed.
NCT02564562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02564562 about?
NCT02564562 is a clinical study titled "A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers". The study aims to understand, using radiolabelled PF-06463922, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.
What is the current status of trial NCT02564562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-10. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02564562?
The interventions under investigation include: [14C] PF-06463922 (DRUG).
Who is sponsoring clinical trial NCT02564562?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.